Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 14,625	$ 9,954
Prepaid expenses and other current assets	1,591	2,509
Total Current Assets	16,216	12,463
Property and equipment, net	37	223
Long-term note receivable	0	700
Deposits and other assets	4	37
Total Assets	16,257	13,423
Current Liabilities:
Accounts payable	142	395
Accrued liabilities	885	0
Total Current Liabilities	1,027	395
Total Liabilities	1,027	395
Commitments and Contingencies	0	0
Equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 58,295,808 issued and 58,214,326 outstanding and 44,444,230 issued and 44,362,748 outstanding	58	44
Additional paid-in capital	96,430	81,925
Accumulated deficit	(81,258)	(68,941)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	15,230	13,028
Non-controlling interest	0	0
Total Equity	15,230	13,028
Total Liabilities and Equity	$ 16,257	$ 13,423